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Abstract
Background: Unsuccessful treatment outcomes among patients with multi-/extensively- drug resistant tuberculosis (TB)
have hampered efforts involved in eradicating this disease. In order to better understand the etiology of this disease, we
aimed to determine whether single or multiple strains of Mycobacterium tuberculosis (MTB) are localized within lung cavities
of patients suffering from chronic progressive TB.
Methodology/Findings: Multiple cavity isolates from lung of 5 patients who had undergone pulmonary resection surgery
were analyzed on the basis of their drug susceptibility profile, and genotyped by spoligotyping and 24-loci MIRU-VNTR. The
patients past history including treatment was studied. Three of the 5 patients had extensive drug resistant TB.
Heteroresistance was also reported within different cavity isolates of the lung. Both genotyping methods reported the
presence of clonal population of MTB strain within different cavities of the each patient, even those reporting
heteroresistance. Four of the 5 patients were infected with a population of the Beijing genotype. Post-surgery they were
prescribed a drug regimen consisting of cycloserine, a fluoroquinolone and an injectable drug. A 6 month post-surgery
follow-up reported only 2 patients with positive clinical outcome, showing sputum conversion.
Conclusion: Identical spoligotype patterns and MIRU-VNTR profiles between multiple cavities of each patient, characterize
the presence of clonal population of MTB strains (and absence of multiple MTB infection).
Citation: Vadwai V, Daver G, Udwadia Z, Sadani M, Shetty A, et al. (2011) Clonal Population of Mycobacterium tuberculosis Strains Reside within Multiple Lung
Cavities. PLoS ONE 6(9): e24770. doi:10.1371/journal.pone.0024770
Editor: Pere-Joan Cardona, Fundacio ´ Institut Germans Trias i Pujol, Universitat Auto `noma de Barcelona CibeRES, Spain
Received June 13, 2011; Accepted August 17, 2011; Published September 14, 2011
Copyright:  2011 Vadwai et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: The authors have no support or funding to report.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: dr_crodrigues@hindujahospital.com
Introduction
Infection due to a single strain of Mycobacterium tuberculosis
(MTB) was considered as the cause of active tuberculosis (TB)
until early 1970’s when phage typing reported the presence of
more than one infecting strain in a single patient [1,2]. Since then
active TB is thought as a result of either due to: primary infection
with a single strain of MTB (primary TB)/after endogenous
reactivation of primary infection i.e. with same strain (relapse)/
exogenous infection with a second MTB strain (reinfection) or
due to simultaneous infection with two or more strains of MTB
(mixed infection) [1,3]. The latter two forms of TB, possibly the
most vulnerable due to the phenomenon of heteroresistance has
been proven in clinical tuberculosis [4]. Infection with different
MTB strains each having different drug susceptibility pattern
makes it difficult to effectively treat the patient with a correct
combination of anti-tubercular drugs, leading to multi-/exten-
sive- drug resistant (M/XDR) cases. In such cases, the tubercle
bacilli overcomes the host immune defense system and does not
respond to the anti-tubercular treatment (ATT) leading to
chronic progressive disease with formation of cavities, fibrotic
lesions and tissue necrosis in the lungs of patients. Previous
studies have shown that pulmonary resection has shown to be
successful in treatment of such drug resistant cases [5,6]. Thus
for effective pre- and post-operative anti-tubercular treatment,
accurate identification and differentiation between MTB strains is
of prime importance. Few studies have shown the utility of 24-loci
Mycobacterial Interspersed Repetitive Units-Variable Number
Tandem Repeats (MIRU-VNTR), a fingerprinting tool in
detection of mixed infection and sub-clonal population [7,8].
To determine the presence/absence of multiple MTB strains
within lung cavities of patients suffering from chronic progressive
TB, we analyzed multiple cavities from lungs of each of the 5
patients who underwent pulmonary resection surgery by deter-
mining the drug susceptibility profile of each cavity isolate and
further characterizing the bacterial populations present by both,
spoligotyping and 24-loci MIRU-VNTR.
Results
Patient: clinical findings, treatment history and
hospitalization characteristics
Three patients (patients 1, 3 and 5) had previous episodes of
TB for which they were treated successfully to complete recovery.
None of the patients were HIV seropositive (Table 1. provides
details about the demographic and clinical characteristics of
patients). All patients had unilateral lung disease with complete
destruction, reduced air entry on the affected side and were on
anti-tubercular treatment for at least 36 months prior to the date
of surgery. Each patient had at least received an average of
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Deviation) anti-tubercular drugs. Table 2. represents a detailed
treatment history of patients pre- and post- pulmonary resection
surgery. Histological analysis of all cavities confirmed the
presence of TB: caseation necrosis with epitheloid cells, visual
presence of acid fast bacilli and formation of granulomas.
Radiologal scans of all patients showed the presence of more
than one fibrous cavitory lesions in the affected lung. Fig. 1.
shows the radiological scan of patients lung prior to surgery and
Fig. 2. shows the resected lung. Patient 1, 2, 3 underwent surgery
due to persistent smear positive status; patient 4, to avoid
complications due to hemoptysis and patient 5, a result of
continuous discharge of pus from the right lung and expired
within 72 hours post-surgery due to respiratory acidosis and left-
sided pneumonia with septic shock. A follow-up of 6 months post-
surgery, reported only 2 patients (3 and 4) with positive clinical
outcome (AFB smear conversion from positive to negative) while
other 2 patients (patient 1 and 2) showed no clinical improvement
with persistent smear positive status. Table 3. summarizes the
hospitalization characteristics of each patient.
MGIT TB culture, phenotypic drug susceptibility testing
and genetic sequence analysis
All cavities (3 cavities per patient) identified within the resected
lung of each patient were excised and were found to be positive on
AFB smear examination and by MGIT TB culture with an
average time to positivity of 20 days. On the basis of their
phenotypic DST results, patients 1, 2, 4 and patients 3, 5 were
reported as XDR-TB and MDR-TB cases respectively. Patients
with extensive drug resistance had received more number of
treatment regimens before undergoing surgery than those patients
with multi-drug resistance (mean number of regimens 6 Standard
Deviation, 6.3360.57 vs 460) (Table 1). Three cavity isolates
from each of the 3 patients (patients 1, 3, 4) showed identical drug
susceptibility profiles. Patient 2 showed variable drug susceptibility
profile for 6 drugs (Km, Am, Cm, Ethambutol [E], para-
aminosalicylic acid [PAS], Pyrazinamide [Z]) between its three
cavities, while patient 5 showed variable drug susceptibility profile
for only 1 drug (PAS). In-house RLBH assay confirmed the
variable drug susceptible profile for aminoglycosides (Km, Am,
Cm) while repeat phenotypic DST confirmed the variable drug
Table 1. Demographic and clinical characteristics of patients.
Patients
a
Characteristics 1 2 3 4 5
Age (years)/Sex 21/F 26/M 33/F 49/F 25/F
Median (Interquartile range) 26 (25–33)
History Family history of
pulmonary TB;
patient has past
history of extra-
pulmonary TB at
the age of 12 yrs.
None Family history of
pulmonary TB;
patient has past
history of pulmonary
TB at the age
of 16 yrs.
None Past history of pulmonary
TB at the age of 17 yrs.
Number of treatment regimens
before surgery
774 8 5
Median (Interquartile Range) 7 (5–7)
Adherence to treatment
b Irregular medication
c Regular medication
d Irregular medication Regular medication Regular medication
Previous treatment with a quinolone
and injectable agent (other than
first-line agents and Streptomycin)
e
Lfx Mfx, Spafloxacin,
Lfx, Km
Ofx, Sparfloxacin,
Lfx, Cm
Ofx, Km Past medical records
lost by the patient
Treatment with other antibiotics
f Cs, Eto, PAS Eto, PAS Eto, Cs, Clr Eto, PAS, Lzd Past medical records lost
by the patient
Other complaints Fever, cough,
breathlessness,
vomiting, decrease
in appetite
Fever, cough Cough, increase
expectoration during
morning hours
Cough, Diabetis Disturbed sleep,
breathlessness
Risk factors for multiple MTB
infection
Irregular Medication;
family history;
patient past history;
treatment failure
Treatment
Failure
g
Irregular Medication;
family history;
p a t i e n tp a s th i s t o r y ;
treatment failure
Patient had completed
full course of anti-
tubercular treatment;
has twice reported
negative sputum
cultures but after 3
months has
documented relapse
of the disease without
default in treatment.
Past history of TB; this episode
was considered as a relapse
since the patient developed the
disease within a few months
after completing the treatment
regimen.
aAll patients were HIV negative.
bAll patients received treatment from private medical practitioners. All patients (except patient 2) on diagnosis were initiated on category I treatment regimen as per the
guidelines of the National TB programme but with no improvement in condition even after 1 year, they were started on second- and third- line anti-tubercular drugs.
cIrregular Medication, treatment interrupted for more than a month for reasons due to patient.
dRegular Medication, patient took regular prescribed medication as per the instructions of the private medical practitioner.
eFirst-line agents, Isoniazid, Rifampin, Ethambutol, Pyrazinamide; Lfx, Levofloxacin; Mfx, Moxifloxacin; Km, Kanamycin; Ofx, Ofloxacin; Cm, Capreomycin;
fCs, Cycloserine; Eto, Ethionamide; PAS, para-aminosalicylic acid; Clr, Clarithromycin; Lzd, Linezolid.
gTreatment Failure, culture or AFB smear microscopy remaining positive or turning positive even after 6 months of treatment.
doi:10.1371/journal.pone.0024770.t001
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susceptibility profile and genetic sequence analysis of all 5 patients
has been shown in Table 4.
Genotyping
Since all 5 patients possessed risk factors (Table 1) favoring the
presence of multiple MTB infection, both spoligotyping and 24-
loci MIRU-VNTR were performed on all cavity isolates of each
patient to confirm its presence. But both showed the presence of a
clonal population of MTB strain in all cavities of each patient
suffering from chronic progressive TB. None of the 24-loci showed
the presence of more than one allele at a single locus, also ruling
out the probability of presence of sub-clonal population of the
infecting strain. Four patients (patients 1, 2, 4, 5) were found to be
infected with a strain belonging to the Beijing family while only
one patient (patient 3) was infected with a strain of T1 family.
Fig. 3. shows a Unweighted Pair Group Method with Arithematic
Mean (UPGMA) based phylogenetic tree showing comparison of
all cavity isolates from 5 patients based on combined similarities of
both the 24-loci MIRU-VNTR and spoligotyping results.
Discussion
Our findings are similar to that of Kaplan et al. [9] that a clonal
population of M. tuberculosis had localized within the lung forming
multiple cavities, causing tissue necrosis and leading to destruction
of the lung.
Our study reports that, 2/5 patients (all on ATT from the past
36 months) had different drug susceptibility profile (for E, Km,
PAS, Am, Cm, Z) between strains from different cavities of a single
patient i.e. some of them were sensitive for a particular drug while
others were resistant against that same drug. The resistance
profiles of these strains were confirmed on the basis of presence of
mutations in the genes responsible for resistance to R, H, Ofx,
Mfx, Km, Am and Cm. In-house RLBH revealed the presence of
uniform genetic mutations within all cavities for patients reporting
resistance to rifampicin (C531T in rpoB gene), isoniazid (G315C
in katG gene), fluoroquinolones (A94G in gyrA gene) and
aminoglycosides (A1401G in rrs gene). Variable drug susceptibility
profiles for Ethambutol, PAS and Pyrazinamide were confirmed
by repeating the phenotypic DST rather than on the genetic basis
due to the following reasons: 1) genetic analysis for determining
Ethambutol resistance targeting emb306 mutation is debatable
since its presence has been reported even in sensitive strains and
hence was not tested in this study [10,11], 2) a recent study by
Feuerriegel et al. [12] and Mathys et al. [13] have demonstrated
that the much hyped Thr202Ala polymorphism in thyA and
mutations in other genes like folP1, folP2, thyX and dfrA are not
valid makers for PAS resistance and that other mechanisms are
responsible for resistance to PAS, and 3) similarly, genetic analysis
for determining PZA resistance is controversial since many PZA
resistant isolates have shown to have a wild-type sequence,
suggesting that phenotypic DST is essential for determination of
PZA resistance [14]. Due to these inconsistent and unpredictable
results, phenotypic DST was preferred over genetic sequence
analysis to confirm the variable drug susceptibility profile for
Ethambutol, PAS and Pyrazinamide.
The variable drug susceptibility profile (heteroresistance)
reported between different cavity isolates of the same patient
could either be due to multiple MTB strain infection or drug
resistance, a result of non-adherence to-/inadequate- treatment
regimen. To better understand the basis of such heteroresistance,
all cavities isolates were genotyped for better identification;
spoligotyping identified strains from 12 cavities of 4 patients
belonging to the Beijing family and 3 cavities from a single patient
to the T1 family. These findings were confirmed by MIRU-
Table 2. Treatment history of each patient pre- and post- pulmonary resection surgery.
Baseline phenotypic DST
report
a
Phenotypic DST report prior
to surgery
b
Patient
Nos.
Year in which
TB was
diagnosed
Empirical treatment
initiated on
diagnosis Sensitive Resistant Sensitive Resistant
Medication prior
to surgery
c
Medication post
surgery
d
1 2006 H, R, E, Z Km, PAS, Mfx,
Am, Cfz, Cm
S, H, R, E, Z,
Eto, Ofx
PAS, Cfz S, H, R, E, Z, Km,
Eto, Ofx, Mfx, Am,
Cfz, Cm
S, Eto, PAS, Lfx, Cs Km, Eto, Mfx, Cs
2 2006 R, E, Z, Km,
Eto, Mfx
E, Km, Eto,
PAS, Am,
Cfz, Cm
S, H, R, Z,
Ofx, Mfx
E, Cfz S, H, R, Z, Km,
Eto, PAS, Ofx,
Mfx, Am, Cm
H, R, Z, E, PAS,
Sparfloxocin
Eto, Am, Cfz,
Lzd, Cs
3 2005 R, Z, Eto, Ofx,
Lfx, Cs, Clr
S, E, Km, Eto,
PAS, Mfx, Am,
Cfz, Cm
H, R, Z, Ofx,
Cs, Clr
S, Km, Am,
Cfz, Cm
H, R, E, Z, Eto,
PAS, Ofx, Mfx
Eto, Am, Lfx,
Cs, Clr
Eto, Cm, Cs, Clr
4 2006 S, H, R, E, Z S, R, Em, Km,
Eto, PAS, Mfx,
Am, Cfz, Cm
H, Ofx Eto, PAS, Cfz,
Cm
S, H, R, E, Z, Km,
Ofx, Mfx, Am
H, R, Km, Lzd H, Km, Lfx, Lzd
5 2006 S, H, R, E, Z Past medical records lost
by the patient
Km, Am,
Cfz, Cm
S, H, R, E, Z, Eto,
PAS, Ofx, Mfx, Am
H, PAS, Lfx, Cs Am, Cs, Lzd, Clr
S, Streptomycin; H, Isoniazid; R, Rifampicin; E, Ethambutol; Z, Pyrazinamide; Km, Kanamycin; Eto, Ethionamide; PAS, para-aminosalicylic acid; Ofx, Ofloxacin; Mfx,
Moxifloxacin; Am, Amikacin; Cfz, Clofaziamine; Cm, Capreomycin; Lfx, Levofloxacin; Cs, Cycloserine; Clr, Clarithromycin; Lzd, Linezolid.
aBaseline phenotypic DST report, the initial phenotypic DST report provided by the patient during counseling. This test was done at another laboratory with no
information about its accreditation.
bThis test was performed on the patients sputum specimen, 3–6 months prior to surgery at the ‘Revised National Tuberculosis Control Programme’ accredited
Mycobacteriology laboratory at our hospital. The test provided drug susceptibility pattern to 13 drugs: S, H, R, E, Z, Km, Eto, PAS, Ofx, Mfx, Am, Cfz and Cm.
cThis medication was prescribed by a private medical practitioner who referred the patient to our hospital for further treatment.
dThis medication was prescribed by the consultant chest physician at our hospital.
doi:10.1371/journal.pone.0024770.t002
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indicating presence of clonal population of MTB strain unlike
other studies wherein multiple infection and/or sub-clonal
population have been reported in clinical samples [4,7]. The
presence of a clonal population and variable drug resistance
profile, indicates that resistance against these drugs had been
acquired recently and independently at different focal sites in the
lung. Subsequently with time, this drug-resistant strain could
Figure 1. Radiological image of the lungs of a patient before surgery.
doi:10.1371/journal.pone.0024770.g001
Figure 2. Resected lung with multiple cavities, area of tissue necrosis and granulomatous inflammation.
doi:10.1371/journal.pone.0024770.g002
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tubercular drugs to replicate and outgrow the sensitive strain. In
such cases, treatment regime should target both drug sensitive-
and resistant- organisms to completely act on and kill the drug
sensitive organisms. For example, improved outcomes for patients
with MDR-TB who were receiving therapy involving Isoniazid
together with the other drugs has been reported [15].
This study also documents the use of inadequate treatment
regimen to treat M/XDR-TB prior to surgery (table 2). Treatment
regimens relied heavily on first-line drugs (H, R) instead of the
recommended regimen consisting of a three second-line drugs, 2–3
third line drugs and an injectable to which the isolate is susceptible
(if available), in case of extensive drug resistant patients [16]. The
extensive drug resistance observed prior to surgery left the surgeon
and referral hospital clinicians with restricted ability to adjust drug
regimens post surgery. The regimen post surgery included later
generation fluoroquinolones, Moxifloxacin or Levofloxacin and/
or other third-line agents like Clofaziamine, Clarithromycin,
Cycloserine or Linezolid. Although the evidence of positive
outcomes of such treatment regimens is limited, we cannot
exclude the possibility that they might provide treatment success
by increasing the regimens activity or by providing protection to
the emergence of resistance to more active agents [17].
The second important finding of the study, in spite of the
presence of risk factors (like non-adherence to-/inadequate-
treatment, past history and/or contact with an active TB person)
indicative of multiple MTB infection, all patients were found to be
infected with only a single infecting MTB strain. Four of the 5
patients included in the study were infected by M. tuberculosis strain
belonging to the Beijing family. Based on the risk factors, we
hypothesize that the patient could be infected by multiple MTB
strains but over a treatment period of 36 months, the dominant strain
of MTB could have outgrown other strains. This dominant strain
withtimecouldhaveundergonegeneticevolutionbyaccumulationof
mutations conferring drug resistance, thus making the strain resistant
to a broad-spectrum of anti-tubercular drugs [18].
Besides the 2 important findings, our study also has several
limitations:
1) The small sample size makes it difficult to determine possible
risk factors that could lead to chronic progressive disease.
Also, all the findings reported need to be confirmed by a
study on a larger sample size.
2) The drug susceptibility tests were performed on the culture
isolate after in vitro growth of MTB strain and not directly on
the specimen itself. In presence of multiple MTB infection,
the dominant strain may outgrow the other strain. This could
lead to an unreliable and inaccurate determination of drug
susceptibility pattern, forming the basis for an ineffective
treatment regimen.
2) This emphasizes the need for development of novel
diagnostic tools for determination of drug susceptibility
profile directly from clinical specimens.
3) Though 24-loci MIRU-VNTR can detect multiple MTB
infections even if one of them is underrepresented at 1% of
the total bacterial population, the detection of clonal
heterogeneity in clinical isolates is difficult. It requires the
analysis of multiple independent colonies unlike this study
wherein a single colony isolate was used for genotyping. A
recent study by Gardy et al. [19], has reported the use of
whole genome sequencing in differentiating strains with
identical MIRU-VNTR profiles.
In conclusion, the study reports the presence of clonal
population of MTB strain, in some cases exhibiting heteroresis-
tance within multiple cavities of a patient. Inadequate-/non-
adherence- to treatment regimen, could be an additional risk
factor (needs further evaluation) contributing to this form of the
disease. These findings also address the need for the development
of alternate rapid interventions that will improve treatment
outcomes, as well as interrupt the transmission of this extensively
drug resistant TB.
Table 3. Hospitalization characteristics and outcomes of individual patients undergoing pulmonary resection surgery.
Patients
Characteristics 1 2 3 4 5
a
No. of days of hospitalization
during the time of surgery
17 15 14 13 6
Median (Interquartile Range) 14 (13–15)
Type of surgery (Affected lung) Pneumectomy
(Left)
Pneumectomy
(Left)
Pneumectomy
(Left)
Lobectomy
(Lower Left)
Partial pneumectomy
(right)
No. of months from treatment
initiation to surgery
42 36 54 36 36
Median (Interquartile Range) 36 (36–42)
Reason to undergo surgery Persistent smear
positive status.
Persistent smear
positive status.
Persistent smear
positive status.
Avoid complications
arising due to
hemoptysis.
Continuous
discharge of pus from
the right lung.
Outcome
b No clinical
improvement, with
persistent smear
positive status
No clinical
improvement, with
persistent smear positive
s t a t u sa n ds p r e a do n
infection in the right lung
Positive clinical
outcome - positive
smear status
conversion to smear
negative
Positive clinical
outcome - positive
smear status
conversion to smear
negative
Expired.
aPatient 5, underwent a partial right pneumectomy 1K years back in another private hospital, and expired with 72 hours post-surgery due to respiratory acidosis and
left-sided pneumonia with septic shock.
bOutcome, is based on the follow-up 6-month post-surgery.
doi:10.1371/journal.pone.0024770.t003
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Study setting and Ethical approval
This study was carried out in a private tertiary referral care
hospital in Mumbai. This study was approved by the National
Health and Education Society, P. D. Hinduja National Hospital
and Medical Research Centre. Written consent was also obtained
from each patient.
Patients
Five patients (patients 1–5) unsuccessfully treated for TB underwent
pulmonary resection surgery from June 2009 to July 2010 were
included in the study. Patient 5 had undergone a partial pneumectomy
of the affected lung 1K years back in another private hospital. Drug
susceptibility testing of sputum specimen of each patient was carried
out in the Mycobacteriology laboratory of this hospital prior to surgery.
Past history and treatment history of each patient was studied.
MGIT TB culture
On arrival of the untreated lung, all cavities (3 cavities in each of
the 5 patients) were identified in the resected lung of each patient
and excised using a sterile blade in a biosafety cabinet II. These
cavities were processed for mycobacterial culture: processed with
N-acetyl L-cysteine and sodium hydroxide (NALC–NaOH) [20],
Table 4. Phenotypic drug susceptibility profile and genetic sequence analysis of all cavities of each patient.
Patient
Nos. Cavity Nos. (Lobe)
a Phenotypic Drug Susceptibility profile
b Genetic sequence analysis: mutation observed (codon number)
c
Sensitive Resistant rpoB gene katG gene gyrA gene rrs gene
1 1 (LUL), 2 (LUL),
3 (LUL)
PAS, Cfz S, H, R, E, Km, Eto,
Ofx, Mfx, Am, Cm, Z
C to T (531) G to C (315) A to G (94) A to G (1401)
2 1 (LUL) Cfz, Z S, H, R, E, K, Eto, PAS,
Ofx, Mfx, Am, Cm
C to T (531) G to C (315) A to G (94) A to G (1401)
2 (LUL) E, Km, Am, Cm, Z, Cfz S, H, R, Eto, PAS, Ofx, Mfx C to T (531) G to C (315) A to G (94) wt
d
3 (LLL) E, PAS, Cfz S, H, R, K, Eto, Ofx, Mfx,
Am, Cm, Z
C to T (531) G to C (315) A to G (94) A to G (1401)
3 1 (LUL), 2 (LLL), 3 (LLL) S, Km, Am, Cfz, Cm H, R, E, Eto, PAS, Ofx, Mfx, Z C to T (531) G to C (315) A to G (94) Wt
4 1 (LUL), 2 (LUL),
3 (LUL)
Cfz S, H, R, E, Km, Eto, PAS,
Ofx, Mfx, Am, Cm, Z
C to T (531) G to C (315) A to G (94) A to G (1401)
5 1 (RUL) Km, PAS, Am, Cfz, Cm S, H, R, E, Eto, Ofx, Mfx, Z C to T (531) G to C (315) A to G (94) wt
2 (RUL) Km, Am, Cfz, Cm S, H, R, E, Eto, PAS, Ofx,
Mfx, Am, Z
C to T (531) G to C (315) A to G (94) wt
3 (RLL) Km, Am, Cfz, Cm S, H, R, E, Eto, PAS,
Ofx, Mfx, Am, Z
C to T (531) G to C (315) A to G (94) wt
aLUL, Left upper lobe; LLL, left lower lobe, RUL, right upper lobe; RLL, right lower lobe.
bS: Streptomycin, H:Isoniazid, R:Rifampicin, E:Ethambutol, Km:Kanamycin, Eto:Ethionamide, PAS:para-aminosalicylic acid, Ofx:Ofloxocin, Mfx:Moxifloxacin, Am:Amikacin,
Cfz:Clofaziamine, Cm:Capreomycin, Z:Pyrazinamide.
cCavity isolates showing variable drug susceptibility profiles were analyzed by in-house RLBH (except for Ethambutol, PAS, Pyrazinamide, wherein phenotypic DST were
repeated to confirm the variable drug susceptibility profile).
dwt – wild type.
doi:10.1371/journal.pone.0024770.t004
Figure 3. UPGMA tree showing the comparison of the cavity isolates from 5 patients based on the combined similarities of both the
24-loci MIRU-VNTR and spoligotype results determined by using the categorical coefficient. Clustered isolates are labeled with a bar.
From left to right are shown: box consisting of the MTB lineage and patient number (cavity no.), and spoligotype pattern.
doi:10.1371/journal.pone.0024770.g003
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[21] and liquid medium (BACTEC MGIT [mycobacteria growth
indicator tube] 960 culture; BD Microbiology Systems). Culture
positives were confirmed for MTB species by p-nitro benzoic acid
assay [21].
Phenotypic DST and genetic sequence analysis
Phenotypic drug susceptibility testing (DST) for first- [22] and
second- line drugs [23] was carried out on all cavity culture isolates
of each patient. Isolates from different cavities within a single
patient showing variable phenotypic drug susceptibility profile
were confirmed either by repeating the phenotypic DST and/or
processing the isolates for genetic sequence analysis using in-house
Reverse Line Blot Hybridization (RLBH) assay targeting specific
gene mutations conferring resistance to first-line drugs like
Rifampicin (R) and Isoniazid (H), and second-line drugs like
aminoglycosides (Kanamycin [Km], Amikacin [Am], Capreomy-
cin [Cm]) and fluoroquinolones (Ofloxacin [Ofx], Moxifloxacin
[Mfx]) [24].
Genotyping
All cavity culture isolates grown on solid media were genotyped
by Spoligotyping (Isogene, Netherlands [as per the manufacturer’s
instructions]) and 24-loci MIRU-VNTR [25] to confirm the
presence or absence of multiple MTB infection.
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